AHK-Cu

AHK-Cu Research Overview

AHK-Cu is a copper-bound tripeptide closely related to GHK-Cu that is used mainly for hair growth. It is applied topically to the scalp, often with microneedling, and has cell and small human study evidence for stimulating hair follicle cells.

Also known as: Copper tripeptide AHK, Alanyl-histidyl-lysine copper, AHK copper complex

Background

AHK-Cu is a synthetic tripeptide of alanine, histidine and lysine bound to a copper ion. It was developed as a variation on the naturally occurring GHK-Cu, swapping the first amino acid to see whether the copper-binding peptide family could be tuned toward specific effects. Where GHK-Cu is used broadly for skin, AHK-Cu found its niche in hair research after cell studies showed it stimulated the dermal papilla cells at the base of hair follicles.

The evidence is mostly laboratory work. In cultured human dermal papilla cells, AHK-Cu increased cell proliferation, reduced apoptosis and upregulated VEGF, the growth factor that supplies follicles with blood. It also inhibited the enzyme that converts testosterone to DHT in some studies, which would be relevant to pattern hair loss. A small Korean clinical study of a topical AHK-Cu solution reported increased hair count and thickness over several months.

Beyond hair, AHK-Cu shares the collagen-stimulating and antioxidant properties of GHK-Cu and is included in some anti-aging skin serums, though it has far less skin-specific data than its better known relative. There are no injectable studies and injection is not a typical route. It is sold as a lyophilized powder for reconstitution into topical solutions and as a ready-made serum ingredient. Most people who use it are treating early to moderate thinning and combine it with established treatments rather than relying on it alone.

Mechanistic Profile

In those cells it raises VEGF expression, which increases blood supply to the follicle, and it activates survival signaling that reduces cell death. It also appears to lower the activity of 5-alpha reductase, the enzyme that makes DHT, the hormone most responsible for follicle shrinkage in pattern hair loss. The copper component supports lysyl oxidase and other enzymes involved in extracellular matrix building, which strengthens the tissue around the follicle. These effects together are meant to prolong the growth phase and reverse miniaturization.

Reported Research Findings

• Stimulated proliferation and reduced apoptosis of human dermal papilla cells in culture. (in vitro)

• Increased VEGF expression and decreased TGF-beta1 in dermal papilla cells, both favoring hair growth. (in vitro)

• Inhibited 5-alpha reductase activity in hair follicle cells, reducing DHT production. (in vitro)

• Topical AHK-Cu increased hair count and hair thickness in a small clinical study of men with pattern hair loss. (human pilot)

Analytical Validation, Formulation and Storage

• Purity: 99% or higher as verified by HPLC, with a third-party certificate of analysis available per batch.

• Formulation: lyophilised (freeze-dried) powder in a sterile sealed glass vial, to be reconstituted with an appropriate solvent for laboratory use.

• Reported half-life: Not applicable for topical use; local tissue action.

• Storage: keep lyophilised material cool, dark and dry (long-term at or below -20 °C). Store reconstituted solutions refrigerated, avoid repeated freeze-thaw cycles and use within laboratory-defined windows.

Selected Literature

• The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research, 2007.

• Copper tripeptide AHK-Cu stimulates dermal papilla cell proliferation and VEGF expression. Journal of Dermatological Science, 2007.

• Copper peptides in hair growth and skin regeneration (review). Journal of Cosmetic Dermatology, 2015.

Cloud Aminos supplies AHK-Cu as a high-purity research material intended strictly for controlled laboratory use in vitro or in established animal models. This compound is not approved as a drug, diagnostic or dietary ingredient and is not manufactured, packaged or marketed for human consumption, self-experimentation, clinical application or any use outside properly designed and ethically approved research protocols.